Compare ARK Genomic Revolution ETF (ARKG) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Enovix Corporation — how do they compare? ARK Genomic Revolution ETF trades at $44.31, while Enovix Corporation trades at $4.9 (market cap $1.01B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | ENVX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $13.19 |
52-Week Low | $24.02 | $3.68 |
Market Cap | — | $1.01B |
Enterprise Value | — | $1.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
ENVX trades at $4.70, up 10.33% today, with a bullish technical signal despite negative profitability. Recent earnings beats and a $12.38 consensus price target suggest upside potential. The company is ramping production of advanced silicon-anode batteries, with key developments including a new COO appointment and upcoming Q2 2026 results on August 12, 2026.
Outlook remains speculative with high revenue growth potential but persistent losses; risks include cash burn and competitive pressures. Analyst sentiment is positive (75% buy ratings), but investors should weigh the long-term growth story against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
